Cortexyme/$QNCX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cortexyme
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
Ticker
$QNCX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
36
ISIN
US22053A1079
Website
Cortexyme Metrics
BasicAdvanced
$59M
-
-$1.40
0.83
-
Price and volume
Market cap
$59M
Beta
0.83
52-week high
$1.60
52-week low
$0.72
Average daily volume
318K
Financial strength
Current ratio
4.048
Quick ratio
3.891
Long term debt to equity
84.22
Total debt to equity
84.769
Profitability
EBITDA (TTM)
-37.753
Effective tax rate (TTM)
-0.17%
Management effectiveness
Return on assets (TTM)
-17.80%
Return on equity (TTM)
-130.90%
Valuation
Price to book
3.08
Price to tangible book (TTM)
-1.31
Price to free cash flow (TTM)
-1.687
Free cash flow yield (TTM)
-59.28%
Free cash flow per share (TTM)
-77.06%
Growth
Earnings per share change (TTM)
79.89%
3-year earnings per share growth (CAGR)
-22.20%
Cortexyme News
AllArticlesVideos
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
Business Wire·2 days ago
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
Business Wire·1 week ago
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cortexyme stock?
Cortexyme (QNCX) has a market cap of $59M as of June 21, 2025.
What is the P/E ratio for Cortexyme stock?
The price to earnings (P/E) ratio for Cortexyme (QNCX) stock is 0 as of June 21, 2025.
Does Cortexyme stock pay dividends?
No, Cortexyme (QNCX) stock does not pay dividends to its shareholders as of June 21, 2025.
When is the next Cortexyme dividend payment date?
Cortexyme (QNCX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cortexyme?
Cortexyme (QNCX) has a beta rating of 0.83. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.